Navigation Links
Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Date:6/30/2008

Company Announces Revised Operating Plan to Respond to NEBIDO Delay

LEXINGTON, Mass., June 30 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NEBIDO(R) related to a New Drug Application (NDA) submitted to the FDA in August 2007. The letter, received on June 27, 2008, indicated that the application may be approved if the Company is able to adequately respond to certain clinical deficiencies related to the product. The letter generally confirmed the Company's previously-announced indications from the FDA based on telephone discussions.

The FDA has expressed a concern about a relatively small number of patients in European post-marketing use who have experienced respiratory symptoms immediately following the intramuscular injection of NEBIDO 1000 mg, 4 cc injection volume, (versus the 750 mg, 3 cc injection volume used in the United States). The Company believes and the FDA concurs that the reaction is likely the result of a small amount of the oily solution immediately entering the vascular system from the injection site, a known, rare complication of oil-based depot injections.

The phenomenon is characterized by short-term reactions involving an urge to cough, coughing episodes or a shortness of breath. In rare cases the reaction has been classified as serious or the patient experiences other symptoms such as dizziness, flushing or fainting. In the Company's U.S. clinical trials of NEBIDO 750 mg (3 cc injection volume), the proposed dose in the U.S., there was a single, mild, non-serious case of oil-based cough observed. In addition, the FDA believes that four cases in the European post-
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Indevus Announces Management Changes
2. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
3. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
4. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
7. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
8. Indevus Announces Allergan as New Partner for SANCTURA Brand
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Alfacell Receives NASDAQ Non-Compliance Notification
11. Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... New Jersey, November 26, Rosetta Genomics (Nasdaq: ... results on December 5, 2008, before the,U.S. markets open. ... webcast to discuss these results at 8:30 a.m. ET ... To access the live conference call, U.S. and ...
... MENLO PARK, Calif., Nov. 26 Evalve, Inc., ... percutaneous repair of cardiac valves,announced today that the ... MitraClip(R) system at the University of Hull, Castle ... is the first commercially,available medical device which provides ...
... 26 Aldrich, a division of,Sigma-Aldrich (Nasdaq: ... Science catalog. The catalog features more than 4,000 ... Ceramic Science,Nanomaterials, Micro/NanoElectronics and Polymer Science. Each chapter,contains ... advances,in these fields. , ...
Cached Biology Technology:Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 3Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research 2
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... A new report from the Institute of Medicine says ... at least 60 minutes of vigorous or moderate intensity ... half of American youth meet current evidence-based guidelines of ... physical activity daily, according to the report, which was ... for nearly half of their waking hours, the committee ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
... might one day avoid the prospect of invasive breast ... involve using stem cells derived from their own fat, ... potential these cells may have for regenerating new breast ... to prove that an injection of fat-derived stem cells ...
... bees, neuropeptides control brain activity and, hence, our behaviors. Understanding ... honey bee will assist researchers in understanding the roles they ... neurons in the brain of a honey bee (Apis mellifera), ... period at the end of this sentence. The activities of ...
... covering almost half the animal species on the planet has ... relationships between four major groups of insects. , ... related to beetles and more distantly related to bees and ... are published in the special Honey Bee Genome issue of ...
Cached Biology News:Fat stem cells being studied as option for breast reconstruction 2Scientists identify 36 genes, 100 neuropeptides in honey bee brains 2New genetic analysis forces re-draw of insect family tree 2
... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
... joined forces with the Mickle Laboratory Engineering ... Chopper. This tissue sectioning system has been ... metabolic experiments and to be especially applicable ... biopsy or from small organs. Its special ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... easy grip) Mfr Desig: ...
... fluorescence scanner with 1 or 2 color(s), ... CGH, ) spotted on standard slides combining ... scanners include three different models:, ... dual fluorescence scanner (635nm and 532nm). , ...
Biology Products: